Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hong Kong-based pharmaceutical company Advance Pharmaceutical has got license for marketing and selling Boston Therapeutics' chewable dietary supplement SugarDown in China.
Subscribe to our email newsletter
SugarDown works in the gastrointestinal tract helps people to manage their glycemic health.
As per the terms of the agreement, Boston Therapeutics is responsible to manufacture and supply the supplement in bulk to the Hong Kong-based pharma firm.
Further, Boston Therapeutics has licensed Advanced Pharma for the development and manufacturing of SugarDown for commercial sale in the region.
In addition to the licensing agreement, Advance Pharmaceutical made an equity investment in Boston Therapeutics to support clinical trials on SugarDown.
Boston Therapeutics president Ken Tassey said they believe Advance’s experience in product development, regulatory, licensing, marketing, distribution and international trade provide valuable growth opportunities for Boston Therapeutics.
Advance Pharma director Conroy Cheng said in strong, preliminary data on volunteers, SugarDown shows the potential to alter the way that pre-diabetic and diabetic people will regulate their carbohydrate consumption and, as a consequence, their blood glucose level.